Acute myelogenous leukemia (Acute myeloid leukemia, AML), is a myeloid hematopoietic bud cells (rather than lymphocytic bud cells) abnormal proliferation of blood malignancies. Characterized by abnormal bone marrow cells in rapid proliferation of shoots affected by the emergence of normal hematopoietic cells. Acute myelogenous leukemia are the most common adult acute leukemia, and its incidence rate as the age increased. Relative to other cancer, acute myeloid leukemia is relatively rare diseases, from cancer in the United States about the numbers of deaths of 1.2%.
Because leukemia cells are replacing the normal bone marrow cells caused by, resulting in peripheral blood of red blood cells, platelets and normal white blood cell decreased. Its symptoms include fatigue, easy to breath, decreased exercise capacity, easy bruising and bleeding, and increased risk of infection.
FAB is the France-America-British abbreviation. The classification published in the 1970s, at the time is ripe for diagnostic techniques to classify. Divided into seven original type, then add the first zero-based.
Acute myelogenous leukemia is a potentially curable disease. Overall, the use of chemical treatment can make about 40% of patients in complete remission, a small number of acute myelogenous leukemia, for example: acute myeloid leukemia, because it is all-trans retinoic acid treatment, the cure rate up to 80 % or more. Treatment to chemotherapy. Hematopoietic stem cell transplantation can be used in poor prognosis of acute myeloid leukemia type.
No comments:
Post a Comment